Survival rates analysis on chemotherapy regimens of patient withcolorectal cancer (A study at division of hematology and medicaloncology Universitas Airlangga teaching hospital)
Main Article Content
Keywords
survival, colorectal cancer, chemotherapy, folfox, folfiri
Abstract
Background: The 5-year survival rate for patients with colorectal cancer decreases in the presence of metastases. Standard therapy for colorectal cancer includes FOLFOX (5- fluorouracil, leucovorin, and oxaliplatin) and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) which aims to prolong survival. Objective: To analyze the survival rate and hazard ratio (HR) of colorectal cancer patients treated at Universitas Airlangga Teaching Hospital Surabaya with the FOLFOX and FOLFIRI chemotherapy regimens. Method: A retrospective cohort approach was used in this study of 39 colorectal cancer patients over the age of 18 who had FOLFOX and FOLFIRI treatment between 2018 and 2022. Results: This study involved 27 colorectal cancer patients who got FOLFOX therapy and 12 patients who received FOLFIRI therapy. FOLFOX had a two-year survival rate of 51.9% with a mean time of 18.2 2.01 months, while FOLFIRI had a two-year survival rate of 58.3% with a mean time of 18.8 1.51 months (p > 0.05), according to Kaplan- Meier analysis. Patients who had incomplete FOLFOX regimens (<12 cycles) had a 3.8-fold higher probability of mortality than those who received a complete regimen (12 cycles) (HR 3.883; 95% CI 1.195-12.169). Conclusion: Patients who take FOLFOX have a lower risk of adverse effects than those who take FOLFIRI, which may influence clinician preferences. The FOLFOX regimen is recommended for colorectal cancer treatment, especially in early and advanced stages, due to potential adverse effects.
References
2. Alcindor Beauger. Oxaliplatin: a review in the era of molecularly targeted therapy. 2011;18.
3. Boyle JM, Kuryba A, Cowling TE, van der Meulen J, Fearnhead NS, Walker K, et al. Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study. International Journal
of Cancer. 2022;150(2):335-46. https://doi.org/10.1002/ijc.33806
4. de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. In Clinical Pharmacokinetics. Springer International Publishing.
2018;57(10):1229-54. https://doi.org/10.1007/s40262- 018-0644-7
5. do Prado TÁ, Del Bel GV, Levignali MB, Resende U. Oxaliplatin versus Irinotecan no câncer colorretal avançado. In Medicina (Brazil) Faculdade de Medicina de Ribeirao Preto - U.S.P. 2022;55(3). https://doi.org/10.11606/issn.2176- 7262.rmrp.2022.189669
6. Ikoma N, Raghav K, Chang G. An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. In Surgical Oncology Clinics of North America. W.B. Saunders. 2017;26(4):667-87. https://doi.org/10.1016/j.soc.2017.05.007
7. INA Wiratama, W Djatmiko, IR Ardiansyah, MB Salipi, AFN Ilmi, N Maharani. Comparative study: Side effects of Folfox4 and folfiri for colorectal cancer chemotherapy regiment in Margono Soekarjo Hospital, Purwokerto. Annals of Oncology. 2018;
29(supply 9). https://doi.org/10.1093/annonc/mdy431
8. Jeo W, Subrata F. The Survival Rate of Colorectal Cancer in dr. Cipto Mangunkusumo Hospital. The New Ropanasuri. Journal of Surgery. 2020;5(2):13-7. https://doi.org/10.7454/nrjs.v5i2.1081
9. Kanat O, Ertas H, Caner B. Platinum-induced neurotoxicity: A review of possible mechanisms. In World Journal of Clinical Oncology. Baishideng Publishing Group Co, Limited. 2017;8(4):329-33. https://doi.org/10.5306/wjco.v8.i4.329
10. Kementrian Kesehatan. Keputusan Menteri Kesehatan Formularium Nasional NOMOR. 2021; HK.01.07/MENKES/6485/2021.
11. Kogan LG, Davis SL, Brooks GA. Treatment delays during FOLFOX chemotherapy in patients with colorectal cancer: A multicenter retrospective analysis. Journal of Gastrointestinal Oncology. 2019;10(5):841-6. https://doi.org/10.21037/jgo.2019.07.03
12. Marsh S, Hoskins JM. Irinotecan pharmacogenomics. In Pharmacogenomics. 2010;11(7):1003-10 https://doi.org/10.2217/pgs.10.95
13. Mitry E. Colorectal Cancer. In International Encyclopedia of Public Health. Elsevier Inc. 2017;75-81. https://doi.org/10.1016/B978-0-12-803678-5.00081-3
14. Munker S, Gerken M, Fest P, Ott C, Schnoy E, Fichtner-Feigl S, et al. Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects. BMC Cancer. 2018; 18(1):455. https://doi.org/10.1186/s12885-018-4380-z
15. NCCN. NCCN 2022 Colorectal Cancer. NCCN Guidelines for Colon Cancer and Rectal Cancer 1.2022, 1(Colorectal Cancer). 2022
16. Neugut AI, Lin A, Raab GT, Hillyer GC, Keller D, O’Neil DS, et al. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clinical Colorectal Cancer. 2019;18(2):133-40. https://doi.org/10.1016/j.clcc.2019.01.005
17. Nishida K. Oxaliplatin: Molecular Mechanisms of Taste Disorder in Oxaliplatin- administered Rats. 2016;136(7):1017-21. https://doi.org/10.1248/yakushi.15-00212
18. Palmieri LJ, Dubreuil O, Bachet JB, Trouilloud I, Locher C, Coriat R, et al. Reasons for chemotherapy discontinuation and endof-life in patients with gastrointestinal cancer: A multicenter prospective AGEO study. Clinics and Study in Hepatology and
Gastroenterology. 2021;45(1):101431. https://doi.org/10.1016/j.clinre.2020.03.029
19. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. In Przeglad Gastroenterologiczny. Termedia Publishing House Ltd. 2019;14(2):89-103. https://doi.org/10.5114/pg.2018.81072
20. Simonson C. Colorectal Cancer - An Update for Primary Care Nurse Practitioners. Journal for Nurse Practitioners. 2018;14(4):344-50. https://doi.org/10.1016/j.nurpra.2017.12.030
21. Stein A, Voigt W, Jordan K. Review: Chemotherapy-induced diarrhea: Pathophysiology, frequency and guideline-based management. In Therapeutic Advances in Medical Oncology. 2010;2(1):51-63. https://doi.org/10.1177/1758834009355164
22. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. Journal of Clinical Oncology. 2004a;22(2):229-37. https://doi.org/10.1200/JCO.2004.05.113
23. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. Journal of Clinical Oncology. 2004b;22(2)229-37. https://doi.org/10.1200/JCO.2004.05.113
24. Tsai YJ, Lin JK, Chen WS, Jiang JK, Teng HW, Yen CC, et al. Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough? SpringerPlus. 2016;5(1):1318. https://doi.org/10.1186/s40064-016-2976-9
25. Van Cutsem E, Borràs JM, Castells A, Ciardiello F, Ducreux M, Haq A, et al. Improving outcomes in colorectal cancer: Where do we go from here? European Journal of Cancer. 2013;49(11):2476-85. https://doi.org/10.1016/j.ejca.2013.03.026
26. Van Eeghen EE, Bakker SD, van Bochove A, Loffeld RJLF. Impact of age and comorbidity on survival in colorectal cancer. Journal of Gastrointestinal Oncology. 2015;6(6):605-12. https://doi.org/10.3978/j.issn.2078-6891.2015.070
27. Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Medicine. 2020;9(1):361-73. https://doi.org/10.1002/cam4.2673
28. White A, Ironmonger L, Steele RJC, Ormiston-Smith N, Crawford C, Seims A. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer. 2018;18(1):906.
https://doi.org/10.1186/s12885-018-4786-7
29. WHO. (2020). Colorectal Cancer. https://doi.org/10.2-15.2
30. Zhu J, Zhang Y, Zhao Y, Zhang J, Hao K, He H. (). Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer. Pharmaceutics. 2023;15(9):2274. https://doi.org/10.3390/pharmaceutics15092274